Evidence map›Paper›PMID 41468896›Full record

ArticleCell reports. Medicine2026

DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity.

Adam P Stockmann, Sylvia Vincent, Lauren Herschelman, Ching-Shin Huang, Jingya Ma, Daniel Fallon, Patrick Kirby, Eva Gutierrez, Danielle Talbot, Stuart W Hicks and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Adam P StockmannDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Sylvia VincentDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Lauren HerschelmanDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Ching-Shin HuangDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Jingya MaDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Daniel FallonDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Patrick KirbyDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Eva GutierrezDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Danielle TalbotDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Stuart W HicksDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Nicolai WagtmannDragonfly Therapeutics, Inc., Waltham, MA 02451, USA.
Ann F CheungDragonfly Therapeutics, Inc., Waltham, MA 02451, USA. Electronic address: ann.cheung@dragonflytx.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DF6215 is a rationally engineered interleukin-2 (IL-2) Fc-fusion protein developed to overcome efficacy and safety limitations of traditional IL-2 cancer immunotherapy. Unlike non-alpha (non-α) IL-2 variants that eliminate CD25 binding and underperform clinically, DF6215 retains moderate IL-2 receptor α (IL-2Rα) affinity while enhancing IL-2Rβγ signaling and extending the half-life via an engineered immunoglobulin (Ig)G1 Fc domain. This design preferentially expands cytotoxic CD8

Indexed as

Antineoplastic AgentsImmunoglobulin Fc FragmentsInterleukin-2NeoplasmsRecombinant Fusion ProteinsAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunotherapyInterleukin-2 Receptor alpha SubunitKiller Cells, NaturalMacaca fascicularisMiceMice, Inbred C57BLAntineoplastic AgentsImmunoglobulin Fc FragmentsInterleukin-2Interleukin-2 Receptor alpha SubunitRecombinant Fusion Proteinscancer immunotherapyDF6215engineered cytokineFc fusionIL-2

Identifiers

PMID41468896
PMCPMC12866164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.